ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option,

[Darryl]

In case you missed this:

ERLEADA

Now Available in the U.S.Addition of 240mg strength allows prescribers flexibility to prescribe one 240mg tablet or four 60mg tablets once-daily based on patient needsHORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States.

The introduction of the 240mg tablet provides the first- and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to prescribe the approved 240mg once-daily dose of ERLEADA® in either one 240mg tablet or four 60mg tablets.

The single-tablet option may be preferable for patients in need of reducing their total number of daily pills.

[Sailing-Todd]

Thanks Darryl. My husband is currently doing well on Apalutamide as a metastatic castration-sensitive prostate cancer (mCSPC). One tablet instead of four sounds a small detail, but psychologically dragging a smaller paper bag back from the pharmacy and having only one pill to swallow can make a big difference!

[Atlpapa]

Do you know if there will be an added cost for the 240mg pill? I would really like to take just one. I know it's psychological but I hate taking 4.

[Darryl Partner in reply to Atlpapa]

That's a question for your insurance provider